Biotech | November 26, 2025
Novartis scores FDA nod for game-changing SMA treatment
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Elevidys came under scrutiny in June when the FDA disclosed two fatal cases in non-ambulatory boys who developed dangerously high liver enzyme levels
These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
Moraine will serve as OTSAW’s exclusive distributor in Japan, deploying the Camello+ autonomous mobile robot and TransCar autonomous guided vehicle to support hospital logistics
The device delivers clear, high-quality images to support accurate diagnoses across a broad range of patient groups
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
Subscribe To Our Newsletter & Stay Updated
